Activated cGAS-STING signaling promotes malignancy in metabolic dysfunction-associated fatty liver disease via mitochondrial DNA and immune cell dysfunction

doi:10.4254/wjh.121423

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(17)

(19)

(0)

(20)

(442)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Jul 27, 2026; 18(7): 121423
Published online Jul 27, 2026. doi: 10.4254/wjh.121423

Table 2 Dynamic changes in liver carnitine palmitoyl transferase-II specific concentration and activity, mean ± SD

Group	n	Average A_IHC (× 100)	Liver CPT-II (ng/mg protein)	Serum CPT-II (U/L)
NC	12	6.93 ± 1.26	124.18 ± 6.58	5.86 ± 2.51
MAFLD	12	2.98 ± 0.83^c	81.24 ± 5.86^c	4.12 ± 1.06^a
MASH	17	0.95 ± 0.78^c	43.68 ± 6.91^c	2.61 ± 0.80^b
LC	15	0.91 ± 0.48^c	40.12 ± 5.58^c	2.18 ± 0.57^c
HCC	10	0.86 ± 0.72^c	36.42 ± 6.88^c	1.98 ± 0.47^c
F value	-	122.599	431.501	20.299
P value	-	< 0.001	< 0.001	< 0.001

^aP < 0.05 vs the normal control (NC) group.

^bP < 0.01 vs the NC group.

^cP < 0.001 vs the NC group.

CPT-II: Carnitine palmitoyl transferase-II; A_IHC: Average absorbance of liver carnitine palmitoyl transferase-II by immunohistochemistry; NC: Normal control; MAFLD: Metabolic dysfunction-associated fatty liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma.

Full Size Table

Citation: Zhou MY, Fang RF, Tang H, Xia XX, Xie Q, Yao DF, Sai WL, Yao M. Activated cGAS-STING signaling promotes malignancy in metabolic dysfunction-associated fatty liver disease via mitochondrial DNA and immune cell dysfunction. World J Hepatol 2026; 18(7): 121423
URL: https://www.wjgnet.com/1948-5182/full/v18/i7/121423.htm
DOI: https://dx.doi.org/10.4254/wjh.121423

Zhou MY, Fang RF, Tang H, Xia XX, Xie Q, Yao DF, Sai WL, Yao M. Activated cGAS-STING signaling promotes malignancy in metabolic dysfunction-associated fatty liver disease via mitochondrial DNA and immune cell dysfunction. World J Hepatol 2026; 18(7): 121423 [DOI: 10.4254/wjh.121423]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.